Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Stayble Therapeutics: BioStock: Stayble adds disc herniation to the pipeline - study approved

Stayble Therapeutics

The pharmaceutical company Stayble Therapeutics has received approval to initiate a clinical phase Ib study with STA363 in patients suffering from chronic disc herniation. In parallel with the disc herniation project, the company is working on completing the phase IIb study in degenerative disc disease, while preparing for future partnerships. With two indications in the portfolio, the company's attractiveness and bargaining power in partnering discussions increase.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/03/stayble-adds-disc-herniation-to-the-pipeline-study-approved/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.